Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric Health at the Crossroads of Climate Change, Food Insecurity, and Malnutrition.

Advances in nutrition (Bethesda, Md.)·2026
Same author

Funnel-based antimicrobial resistance monitoring in Italy: the FUN-IT study.

Scientific reports·2025
Same author

Specialist Healthcare Intervention and Follow-up Trends in Post-Acute COVID-19 Hospitalization as Compared to Other Respiratory Infections.

Infectious diseases and therapy·2025
Same author

Synergising one health and environmental, social, and governance (ESG) standards: A scoping review.

One health (Amsterdam, Netherlands)·2025
Same author

The impact of COVID-19 hospitalizations on nursing home admissions: a regional insight into long-term care and public health.

Frontiers in public health·2025
Same author

Balancing Equity and Global Health Security Towards a Fair and Effective Pandemic Agreement.

International journal of public health·2025
Same journal

Diminished Returns: The Hidden Health Costs of Upward Social Mobility for Black Americans.

Annual review of public health·2026
Same journal

The Epidemiology, Prevention, and Control of Type 2 Diabetes in Low- and Middle-Income Countries.

Annual review of public health·2026
Same journal

Community-Based Participatory Research: Evolution and Significant Developments.

Annual review of public health·2026
Same journal

Causal Inference in Health Disparities Research.

Annual review of public health·2026
Same journal

The Health Implications of Fatherhood: A Comprehensive Literature Review.

Annual review of public health·2026
Same journal

Practice-Focused Research Based on Public Health Critical Race Praxis.

Annual review of public health·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Prospects for tuberculosis elimination.

Christopher Dye1, Philippe Glaziou, Katherine Floyd

  • 1Office of Health Information, World Health Organization, CH 1211 Geneva 27, Switzerland. dyec@who.int

Annual Review of Public Health
|December 19, 2012
PubMed
Summary
This summary is machine-generated.

Achieving tuberculosis (TB) elimination by 2050 requires a 1,000-fold incidence reduction through early detection, high cure rates, and new prevention technologies. New diagnostics, drugs, and vaccines are crucial for preventing infections and treating latent TB.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Related Experiment Videos

Last Updated: May 16, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Area of Science:

  • Public Health
  • Infectious Disease Epidemiology
  • Global Health Security

Background:

  • Tuberculosis (TB) elimination by 2050 necessitates a substantial reduction in annual incidence to less than one case per million.
  • This ambitious goal requires a 1,000-fold decrease in TB incidence within approximately 35 years.
  • Current strategies must be augmented to meet this target.

Purpose of the Study:

  • To outline the necessary strategies and technological advancements for achieving global TB elimination.
  • To identify key milestones, such as reducing TB deaths to less than 1 per 100,000, indicating entry into the elimination phase.
  • To emphasize the dual approach of treating active TB and preventing/neutralizing latent infections.

Main Methods:

  • The study emphasizes a combined strategy of effective treatment for active TB (early case detection, high cure rates) to interrupt transmission.
  • It highlights the need for methods to prevent new infections and neutralize existing latent TB infections.
  • Vigorous implementation of the World Health Organization (WHO) Stop TB Strategy is essential for treating active cases.

Main Results:

  • Achieving TB elimination requires interrupting transmission through early case detection and high cure rates.
  • Preventing new infections and neutralizing latent TB are critical components for elimination.
  • New technologies, including biomarkers, diagnostics, drugs, and vaccines, are vital for addressing latent and preventing new infections.
  • Reaching a milestone of less than 1 TB death per 100,000 population signifies entry into the elimination phase.

Conclusions:

  • Global TB elimination by 2050 is achievable through a comprehensive approach combining treatment, prevention, and technological innovation.
  • The effective supply and demand for health services are crucial for implementing the WHO Stop TB Strategy.
  • New technologies are indispensable for preventing infections and managing latent TB, accelerating progress towards elimination.
  • Many countries can reach the TB elimination phase within one to two decades by meeting key mortality reduction milestones.